TY - JOUR
T1 - No gioke intended
AU - Johnson, James R.
PY - 1994/2
Y1 - 1994/2
N2 - The optimal prophylactic agent for PCP that is currently available is TMP-SMZ; however, this combination is not tolerated by 34% of HIV-infected patients [2]. AP (300 mg/mo) is a secondline agent as, in comparison with TMP-SMZ, it is less efficacious for prophylaxis of PCP, more costly, and not prophylactic for extrapulmonary pneumocystosis [3, 4]. Our patient developed PCP while he was taking AP (300 mg/mo), and he exhibited intolerance to other accepted prophylactic agents. We empiricallyrestarted treatment with AP at a dose of 600 mg twice per month (quadrupling the usual monthly dose), and this regimen was successful as secondary prophylaxis for our patient for> i year.
AB - The optimal prophylactic agent for PCP that is currently available is TMP-SMZ; however, this combination is not tolerated by 34% of HIV-infected patients [2]. AP (300 mg/mo) is a secondline agent as, in comparison with TMP-SMZ, it is less efficacious for prophylaxis of PCP, more costly, and not prophylactic for extrapulmonary pneumocystosis [3, 4]. Our patient developed PCP while he was taking AP (300 mg/mo), and he exhibited intolerance to other accepted prophylactic agents. We empiricallyrestarted treatment with AP at a dose of 600 mg twice per month (quadrupling the usual monthly dose), and this regimen was successful as secondary prophylaxis for our patient for> i year.
UR - http://www.scopus.com/inward/record.url?scp=0028144643&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028144643&partnerID=8YFLogxK
U2 - 10.1093/clinids/18.2.258
DO - 10.1093/clinids/18.2.258
M3 - Article
C2 - 8161642
AN - SCOPUS:0028144643
SN - 1058-4838
VL - 18
SP - 258
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 2
ER -
